JPWO2020072519A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020072519A5 JPWO2020072519A5 JP2021542087A JP2021542087A JPWO2020072519A5 JP WO2020072519 A5 JPWO2020072519 A5 JP WO2020072519A5 JP 2021542087 A JP2021542087 A JP 2021542087A JP 2021542087 A JP2021542087 A JP 2021542087A JP WO2020072519 A5 JPWO2020072519 A5 JP WO2020072519A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ptcl
- cell lymphoma
- antibody
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862739631P | 2018-10-01 | 2018-10-01 | |
| US62/739,631 | 2018-10-01 | ||
| PCT/US2019/054107 WO2020072519A1 (en) | 2018-10-01 | 2019-10-01 | Method of treating peripheral t cell lymphoma using anti-cd30 antibody drug conjugate therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502508A JP2022502508A (ja) | 2022-01-11 |
| JP2022502508A5 JP2022502508A5 (https=) | 2022-10-11 |
| JPWO2020072519A5 true JPWO2020072519A5 (https=) | 2022-10-11 |
Family
ID=68296746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542087A Pending JP2022502508A (ja) | 2018-10-01 | 2019-10-01 | 抗ｃｄ３０抗体薬物複合体療法を使用して末梢性ｔ細胞リンパ腫を処置する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20200102399A1 (https=) |
| EP (1) | EP3860658A1 (https=) |
| JP (1) | JP2022502508A (https=) |
| KR (1) | KR20210069679A (https=) |
| CN (1) | CN113613678A (https=) |
| AU (1) | AU2019355875A1 (https=) |
| CA (1) | CA3114922A1 (https=) |
| IL (1) | IL281920A (https=) |
| MX (1) | MX2021003734A (https=) |
| SG (1) | SG11202103342QA (https=) |
| WO (1) | WO2020072519A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI851577B (zh) | 2018-06-07 | 2024-08-11 | 美商思進公司 | 喜樹鹼結合物 |
| CA3183602A1 (en) * | 2020-05-13 | 2021-11-18 | Seagen Inc. | Methods of treating cancer using a combination of anti-cd30 antibody-drug conjugates |
| JP7652918B2 (ja) | 2021-03-01 | 2025-03-27 | ナントバイオ，インコーポレイテッド | 抗ｃｄ３０モノクローナル抗体及びキメラ抗原受容体 |
| WO2024145637A2 (en) * | 2022-12-30 | 2024-07-04 | The Regents Of The University Of Colorado, A Body Corporate | Immunotoxin-based targeted therapy for cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| AU667460B2 (en) | 1990-10-05 | 1996-03-28 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| EP0557300B1 (en) | 1990-10-29 | 1997-11-19 | Chiron Corporation | Bispecific antibodies, method of production, and uses thereof |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| EP1306095A3 (en) | 1992-03-05 | 2003-06-25 | Board Of Regents, The University Of Texas System | Methods and compositions for targeting the vasculature of solid tumors |
| US7090843B1 (en) | 2000-11-28 | 2006-08-15 | Seattle Genetics, Inc. | Recombinant anti-CD30 antibodies and uses thereof |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
| CA3159253A1 (en) | 2009-01-09 | 2010-07-15 | Seagen Inc. | Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates |
| CN110022938A (zh) * | 2016-11-14 | 2019-07-16 | 千禧制药公司 | 抗cd30抗体药物缀合物的非成年人给药 |
| WO2019089870A1 (en) * | 2017-11-01 | 2019-05-09 | Seattle Genetics, Inc. | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy |
-
2019
- 2019-10-01 MX MX2021003734A patent/MX2021003734A/es unknown
- 2019-10-01 KR KR1020217012841A patent/KR20210069679A/ko not_active Ceased
- 2019-10-01 WO PCT/US2019/054107 patent/WO2020072519A1/en not_active Ceased
- 2019-10-01 JP JP2021542087A patent/JP2022502508A/ja active Pending
- 2019-10-01 CN CN201980071250.5A patent/CN113613678A/zh active Pending
- 2019-10-01 SG SG11202103342QA patent/SG11202103342QA/en unknown
- 2019-10-01 AU AU2019355875A patent/AU2019355875A1/en active Pending
- 2019-10-01 EP EP19791017.7A patent/EP3860658A1/en active Pending
- 2019-10-01 CA CA3114922A patent/CA3114922A1/en active Pending
- 2019-10-01 US US16/589,914 patent/US20200102399A1/en active Pending
-
2021
- 2021-03-31 IL IL281920A patent/IL281920A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230110128A1 (en) | Use of antibody drug conjugates comprising tubulin disrupting agents to treat solid tumor | |
| JPWO2021151984A5 (https=) | ||
| RU2019126562A (ru) | ЛЕЧЕНИЕ ТРИЖДЫ НЕГАТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ, ХАРАКТЕРИЗУЮЩЕГОСЯ ЭКСПРЕССИЕЙ Trop-2, С ПОМОЩЬЮ САЦИТУЗУМАБА ГОВИТЕКАНА И ИНГИБИТОРА Rad51 | |
| JP2021518394A5 (https=) | ||
| JP2020527572A5 (https=) | ||
| JP2006265245A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| JP2020536932A5 (https=) | ||
| JP2021501776A5 (https=) | ||
| JP2015500822A5 (https=) | ||
| JP2021523233A5 (https=) | ||
| JP2021523158A5 (https=) | ||
| JP2021534165A5 (https=) | ||
| Wolska-Washer et al. | Emerging antibody-drug conjugates for treating lymphoid malignancies | |
| WO2025061140A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| Tuscano et al. | Anti-CD22 ligand-blocking antibody HB22. 7 has independent lymphomacidal properties and augments the efficacy of90Y-DOTA-peptide-Lym-1 in lymphoma xenografts | |
| Salifu et al. | Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer | |
| Cheng et al. | Overview of antibody-drug conjugates nonclinical and clinical toxicities and related contributing factors | |
| IL315350A (en) | Methods of reducing side effects of anti-cd30 antibody drug conjugate therapy | |
| JP2022164894A (ja) | 非成人のヒトに対する抗ｃｄ３０抗体－薬物コンジュゲートの投与 | |
| JP2021501800A5 (https=) | ||
| JPWO2020072519A5 (https=) | ||
| Hwang et al. | Emerging egfr-targeted therapy in head and neck cancer: A review | |
| JPH01502909A (ja) | 免疫毒素による人間の治療における免疫抑制 | |
| Rossi et al. | Antibody–drug conjugates for the treatment of hematological malignancies: a comprehensive review |